Comparing the effectiveness of Rosuvastatin and Atorvastatin on changes in LDL, TG and HDL: A systematic review and meta-analysis

IF 5.2 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Life sciences Pub Date : 2025-03-24 DOI:10.1016/j.lfs.2025.123576

Kourosh Sayehmiri , Masoumeh Shohani , SamiraMis Qavam , Hamed Tavan

{"title":"Comparing the effectiveness of Rosuvastatin and Atorvastatin on changes in LDL, TG and HDL: A systematic review and meta-analysis","authors":"Kourosh Sayehmiri , Masoumeh Shohani , SamiraMis Qavam , Hamed Tavan","doi":"10.1016/j.lfs.2025.123576","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><div>Elevated levels of LDL and triglycerides, along with low levels of HDL, are key contributors to cardiovascular disease. If the increase of harmful fats is prevented, it will be a great step towards the prevention of diseases. The two drugs atorvastatin and rosuvastatin are the most commonly used drugs to reduce LDL and triglycerides and increase HDL in patients.</div><div>The present study aimed to compare the effectiveness of Rosuvastatin and Atorvastatin on changes in LDL, TG and HDL using a systematic review and meta-analysis method.</div></div><div><h3>Materials and methods</h3><div>The present study was conducted on the basis of the protocol of systematic review and meta-analyses. The ISI, Cochrane Library, Google Scholar, PubMed, Scopus, and Elsevier databases were independently searched by two researchers using Mesh keywords in different regions of the world during 2003 to 2025. Data was analyzed using the STATA software.</div></div><div><h3>Key findings</h3><div>Effectiveness of Atorvastatin on the reduction of LDL was 51.49 mg/dl (42.75–60.23 %, CI =95 %) versus Rosuvastatin with a reduction of 55.66 mg/dl (46.32–65 and CI =95 %). The effectiveness of Atorvastatin on the rise of HDL was 1.85 mg/dl (−3.23–0.46 and CI =95 %) versus Rosuvastatin with a rise of 3.87 mg/dl (2.08–5.66 and CI =95 %); and the effectiveness of atorvastatin on the reduction of TG was 24.76 mg/dl (18.14–31.88 and CI = 95 %) versus the effectiveness of Rosuvastatin with a reduction of 31.98 mg/dl (24. 41–39.55 and CI = 95 %).</div></div><div><h3>Significance</h3><div>According to research results, Rosuvastatin was better than Atorvastatin and decreased triglyceride and LDL and increased HDL in all cases.</div></div>","PeriodicalId":18122,"journal":{"name":"Life sciences","volume":"370 ","pages":"Article 123576"},"PeriodicalIF":5.2000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Life sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0024320525002103","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

Elevated levels of LDL and triglycerides, along with low levels of HDL, are key contributors to cardiovascular disease. If the increase of harmful fats is prevented, it will be a great step towards the prevention of diseases. The two drugs atorvastatin and rosuvastatin are the most commonly used drugs to reduce LDL and triglycerides and increase HDL in patients.

The present study aimed to compare the effectiveness of Rosuvastatin and Atorvastatin on changes in LDL, TG and HDL using a systematic review and meta-analysis method.

Materials and methods

The present study was conducted on the basis of the protocol of systematic review and meta-analyses. The ISI, Cochrane Library, Google Scholar, PubMed, Scopus, and Elsevier databases were independently searched by two researchers using Mesh keywords in different regions of the world during 2003 to 2025. Data was analyzed using the STATA software.

Key findings

Effectiveness of Atorvastatin on the reduction of LDL was 51.49 mg/dl (42.75–60.23 %, CI =95 %) versus Rosuvastatin with a reduction of 55.66 mg/dl (46.32–65 and CI =95 %). The effectiveness of Atorvastatin on the rise of HDL was 1.85 mg/dl (−3.23–0.46 and CI =95 %) versus Rosuvastatin with a rise of 3.87 mg/dl (2.08–5.66 and CI =95 %); and the effectiveness of atorvastatin on the reduction of TG was 24.76 mg/dl (18.14–31.88 and CI = 95 %) versus the effectiveness of Rosuvastatin with a reduction of 31.98 mg/dl (24. 41–39.55 and CI = 95 %).

Significance

According to research results, Rosuvastatin was better than Atorvastatin and decreased triglyceride and LDL and increased HDL in all cases.

Abstract Image

查看原文本刊更多论文

比较瑞舒伐他汀和阿托伐他汀对低密度脂蛋白、总胆固醇和高密度脂蛋白变化的有效性：系统回顾和荟萃分析

低密度脂蛋白和甘油三酯水平的升高，以及高密度脂蛋白水平的降低，是心血管疾病的关键因素。如果能防止有害脂肪的增加，那将是预防疾病的一大步。阿托伐他汀和瑞舒伐他汀两种药物是患者最常用的降低LDL和甘油三酯和增加HDL的药物。本研究旨在通过系统评价和荟萃分析方法比较瑞舒伐他汀和阿托伐他汀对LDL、TG和HDL的影响。材料和方法本研究采用系统综述和荟萃分析的方法。2003年至2025年间，两名研究人员使用Mesh关键词在世界不同地区独立检索了ISI、Cochrane Library、b谷歌Scholar、PubMed、Scopus和Elsevier数据库。数据分析采用STATA软件。阿托伐他汀降低LDL的有效性为51.49 mg/dl (42.75 - 60.23%, CI = 95%)，而瑞舒伐他汀降低55.66 mg/dl （46.32-65, CI = 95%）。阿托伐他汀对HDL升高的有效性为1.85 mg/dl (- 3.23-0.46, CI = 95%)，而瑞舒伐他汀升高3.87 mg/dl (2.08-5.66, CI = 95%)；阿托伐他汀降低TG的有效性为24.76 mg/dl (18.14-31.88, CI = 95%)，而瑞舒伐他汀降低TG的有效性为31.98 mg/dl(24。41-39.55, CI = 95%)。根据研究结果，瑞舒伐他汀在所有病例中均优于阿托伐他汀，降低甘油三酯和LDL，升高HDL。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Life sciences 医学-药学

CiteScore

12.20

自引率

1.60%

发文量

841

审稿时长

6 months

期刊介绍： Life Sciences is an international journal publishing articles that emphasize the molecular, cellular, and functional basis of therapy. The journal emphasizes the understanding of mechanism that is relevant to all aspects of human disease and translation to patients. All articles are rigorously reviewed. The Journal favors publication of full-length papers where modern scientific technologies are used to explain molecular, cellular and physiological mechanisms. Articles that merely report observations are rarely accepted. Recommendations from the Declaration of Helsinki or NIH guidelines for care and use of laboratory animals must be adhered to. Articles should be written at a level accessible to readers who are non-specialists in the topic of the article themselves, but who are interested in the research. The Journal welcomes reviews on topics of wide interest to investigators in the life sciences. We particularly encourage submission of brief, focused reviews containing high-quality artwork and require the use of mechanistic summary diagrams.